1,318 results on '"Lahuerta, Juan"'
Search Results
2. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
3. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
4. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
5. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
6. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
7. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
8. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
9. Postoperative neurological complications after brachial plexus block: a retrospective study conducted at a teaching hospital
10. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
11. A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
12. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
13. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
14. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
15. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
16. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
17. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
18. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
19. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
20. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
21. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy
22. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
23. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
24. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
25. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
26. P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
27. Signs of prehistory in the artistic economy of l’Esprit Nouveau
28. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
29. Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
30. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
31. AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor
32. Cost Analysis of Low-Volume Versus Standard-Volume Ultrasound-Guided Interscalene Brachial Plexus Block in Arthroscopic Shoulder Surgery
33. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure
34. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
35. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
36. Measurable residual disease in multiple myeloma: ready for clinical practice?
37. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients
38. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
39. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry
40. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
41. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
42. Supplementary Figure from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
43. Figure S1 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
44. Table S2 from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
45. Supplementary Data from A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
46. Online Supplement from Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission
47. Bioavailability of Bioactive Compounds from Reconstituted Grapefruit Juice as Affected by the Obtention Process
48. Cell Count Differentials by Cytomorphology and Next-Generation Flow Cytometry in Bone Marrow Aspirate: An Evidence-Based Approach
49. Composition of Powdered Freeze-Dried Orange Juice Co-Product as Related to Glucose Absorption In Vitro
50. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.